Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.

Abstract excerpt

BTK inhibitors (BTKi) have become standard of care for treatment of patients with chronic lymphocytic leukemia (CLL). Covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib are effective but alterations in the kinase domain at C481 or BTK gatekeeper residue T474 mutations result in development of resistance. Noncovalent BTK inhibitors (ncBTKi) such as pirtobrutinib are effective in patients with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenine
• Share to Agammaglobulinaemia Tyrosine Kinase